Transforming the Treatment of Immune Diseases

Noa Therapeutics is a preclinical biotech company pioneering the development of multimodal therapies. Singular, non-steroidal, small molecules with tunable activity across three inflammatory barrier disease drivers to simplify the course of care for patients in need.

Multi-ethnic woman surrounded by DNA molecules

Breaking Free from Convention

Our immune system’s first line of defense are barriers such as our skin and gut. Impaired barrier function is associated with infection and inflammation, resulting in immune disease.

Current therapeutics for inflammatory barrier diseases focus on symptom relief, particularly inflammation due to the pathophysiological role of inflammatory cytokines in many diseases. However, addressing individual disease drivers in isolation inherently leads to limited efficacy, resulting in poor patient compliance, and unfortunately serious side effects. This current paradigm leaves patients and physicians cycling through trial-and-error treatment failures. 

Noa is embarking on a journey to develop breakthrough multimodal therapeutics to wholly address the complexity of immune diseases. Providing singular therapeutic solutions with meaningful outcomes.

Our Approach

Leveraging a computer assisted drug discovery engine, Noa is leading the discovery of multimodal therapeutic compounds for the tailored treatment of immune diseases. Our suite of singular, non-steroidal, small molecules drive three discrete therapeutic targets, uniquely suited to address the complexity of immune diseases involving barrier dysfunction. 

This differentiated multimodal approach is uniquely suited to address unmet needs in atopic dermatitis as a first use case. By addressing multiple disease drivers and providing an anticipated superior safety profile, Noa is aligned to serve underrepresented and underserved patients inclusive of juvenile and pediatric populations. Creating an opportunity for Noa to redefine immune disease treatment for unprecedented clinical impact.


Laughing boy and grandfather lying on grass

The Impact of Atopic Dermatitis



Persons affected by Atopic Dermatitis in the United States



Majority of cases receive topical therapies. First line: corticosteroids.



Patients dissatisfied with current treatment options

Our Research

Noa Therapeutics is pioneering the development of non-steroidal, multimodal small molecules for the tailored treatment of complex immune diseases involving barrier dysfunction. Adopting a computer assisted drug discovery engine, Noa is working to tune the efficacy profile of their novel drug compounds to address persistent unmet needs, delivering meaningful therapeutics to underrepresented and underserved patients. 

Immune Modulation

Attenuating inflammatory cytokines to promote resolution of chronic inflammation and immune homeostasis

Barrier Restoration

Upregulating epithelial and endothelial barrier proteins for the restoration of homeostatic barrier function

Microbiome Modulation

Broad spectrum antimicrobial efficacy, including antibiotic resistant pathogens, while retaining a null resistance profile

With an expected distinction in safety profile and multimodal therapeutic advantage, Noa aims to provide a long-term solution for the safe, effective, and rapid resolution of immune disease including juvenile and pediatric populations.

 Delivering meaningful outcomes for all patients and those who care for them.

Our Program

 Noa Therapeutics is a preclinical biotech company leveraging a computer assisted drug discovery engine to accelerate the design of tailored multimodal solutions for complex immune diseases involving barrier dysfunction. 

Leveraging this differentiated approach, Noa’s non-steroidal lead drug compound, NOA-104, aims to simultaneously target three disease drivers to address persistent unmet needs within inflammatory barrier diseases. Noa is advancing a first use case in Atopic Dermatitis, with the potential for expansion into secondary dermatological inflammatory diseases. In parallel, Noa is building a portfolio of novel multimodal therapeutics to address systemic inflammatory disease markets including gastrointestinal (ulcerative colitis), central nervous system (multiple sclerosis), ocular, and cardiovascular indications.

Breaking free from the current treatment paradigm, Noa aims to resolve multiple immune diseases drivers. Restoring barrier function while promoting immune homeostasis without compromising systemic immunity. Streamlining treatment into one, singular, therapeutic solution with meaningful outcomes. 

Woman helps a boy riding his bike



Carla Spina PhD

Carla Spina PhD

CEO & Co-Founder

Founding Director. Seasoned innovator. Over 18 years experience in skin and wound device and drugs. Leading discovery through clinical phase study and commercialization.

Serena Mandla P.Eng, MASc

Serena Mandla P.Eng, MASc

CSO & Co-Founder

Experienced innovator in the development, manufacturing, and commercialization of novel small peptides for cardiovascular and skin disease applications.

Board of Directors

Maura Campbell PhD

Maura Campbell PhD

CEO at Ontario Bioscience Innovation Organization

François Ravenelle

François Ravenelle

CEO & President at Inversago Pharma


Changing the Face of Inflammatory Diseases: Noa Therapeutics Secures Pre-Seed Financing to Transform the Treatment of Complex Immune Diseases

Noa Therapeutics, a preclinical stage biotech company with a portfolio of novel trimodal therapeutics to address inflammatory barrier diseases, announced that they have secured an oversubscribed pre-seed financing round.

Read Press Release